SG Sides Against Novo In Dispute Over Generics

Law360, New York (May 26, 2011, 8:30 PM EDT) -- The U.S. solicitor general said Thursday that the U.S. Supreme Court should overturn a ruling in a suit between Caraco Pharmaceutical Laboratories Ltd. and Novo Nordisk A/S that makes it easier for name-brand drugmakers to avoid generic competition.

U.S. Acting Solicitor General Neal Kumar Katyal said that a 2010 Federal Circuit ruling lets brand-name drugmakers file misleading descriptions of their patents in the U.S. Food and Drug Administration's so-called Orange Book — case law that could ultimately stop billions of dollars in legitimate generic drugs from...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.